Real-world efficacy and adverse events of frontline nilotinib in pediatric chronic myeloid leukemia in chronic phase: A prospective multicenter study from SCCCG[PLUS]-CML 2023
Fan Z et al. Cancer, December 2025 – open access publication
Link to full abstract